CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
8 results
Search Results
Now showing 1 - 8 of 8
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Latin American association for the study of the liver (ALEH) guidance on postoperative care after liver transplantation(Elsevier BV, 2025-07); 7Scopus© Citations 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort(2020)13Scopus© Citations 18 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Liver transplantation for hepatocellular carcinoma: impact of expansion criteria in a multicenter cohort study from a high waitlist mortality region(2021)Scopus© Citations 3 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, New Perspectives to Improve Mesenchymal Stem Cell Therapies for Drug-Induced Liver Injury<jats:p>Drug-induced liver injury (DILI) is one of the leading causes of acute liver injury. Many factors may contribute to the susceptibility of patients to this condition, making DILI a global medical problem that has an impact on public health and the pharmaceutical industry. The use of mesenchymal stem cells (MSCs) has been at the forefront of regenerative medicine therapies for many years, including MSCs for the treatment of liver diseases. However, there is currently a huge gap between these experimental approaches and their application in clinical practice. In this concise review, we focus on the pathophysiology of DILI and highlight new experimental approaches conceived to improve cell-based therapy by the in vitro preconditioning of MSCs and/or the use of cell-free products as treatment for this liver condition. Finally, we discuss the advantages of new approaches, but also the current challenges that must be addressed in order to develop safer and more effective procedures that will allow cell-based therapies to reach clinical practice, enhancing the quality of life and prolonging the survival time of patients with DILI.</jats:p>Scopus© Citations 10 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Performance of pre‐transplant criteria in prediction of hepatocellular carcinoma progression and waitlist dropout(2022)2Scopus© Citations 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Direct‐Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait‐List Progression or Posttransplant Recurrence(2020)7Scopus© Citations 15 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comparative evaluation of survival prognosis using MELD or Child-Pugh scores in patients with liver cirrhosis in Chile(2017)9Scopus© Citations 4 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Blood pressure variability and outcome in acute ischemic and hemorrhagic stroke: a post hoc analysis of the HeadPoST study.(2019)6Scopus© Citations 34